Abstract
Summary
Imipenem and cilastatin injection is used to treat certain serious infections that are caused by bacteria, including endocarditis (infection of the heart lining and valves) and respiratory tract (including pneumonia), urinary tract, abdominal (stomach area), gynecological, blood, skin, bone, and joint infections. Imipenem is in a class of medications called carbapenem antibiotics. It works by killing bacteria. Cilastatin is in a class of medications called dehydropeptidase inhibitors. It works by helping imipenem stay active in your body for a longer period of time.
The global Imipenem Cilastatin Sodium API market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Imipenem Cilastatin Sodium API Industry Forecast” looks at past sales and reviews total world Imipenem Cilastatin Sodium API sales in 2023, providing a comprehensive analysis by region and market sector of projected Imipenem Cilastatin Sodium API sales for 2024 through 2030. With Imipenem Cilastatin Sodium API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Imipenem Cilastatin Sodium API industry.
This Insight Report provides a comprehensive analysis of the global Imipenem Cilastatin Sodium API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Imipenem Cilastatin Sodium API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Imipenem Cilastatin Sodium API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Imipenem Cilastatin Sodium API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Imipenem Cilastatin Sodium API.
United States market for Imipenem Cilastatin Sodium API is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Imipenem Cilastatin Sodium API is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Imipenem Cilastatin Sodium API is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Imipenem Cilastatin Sodium API players cover Shandong New Era Pharmaceutical, Shenzhen Haibin Pharmaceutical, Sinopharm Guorui Pharmaceutical, Taiwan Biotech Co., Ltd. and Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Imipenem Cilastatin Sodium API market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
≥99%
≥98%
Segmentation by application
Pharmaceutical
Research
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Shandong New Era Pharmaceutical
Shenzhen Haibin Pharmaceutical
Sinopharm Guorui Pharmaceutical
Taiwan Biotech Co., Ltd.
Merck
Sun Pharmaceutical Industries Ltd.
JW Pharmaceutical
Zhengde Pharmaceutical
Hospira Inc.
WG Critical Care
Hanhui Pharmaceutical
Zhuhai United Laboratories
ACS Dobfar
Key Questions Addressed in this Report
What is the 10-year outlook for the global Imipenem Cilastatin Sodium API market?
What factors are driving Imipenem Cilastatin Sodium API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Imipenem Cilastatin Sodium API market opportunities vary by end market size?
How does Imipenem Cilastatin Sodium API break out type, application?
The global Imipenem Cilastatin Sodium API market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Imipenem Cilastatin Sodium API Industry Forecast” looks at past sales and reviews total world Imipenem Cilastatin Sodium API sales in 2023, providing a comprehensive analysis by region and market sector of projected Imipenem Cilastatin Sodium API sales for 2024 through 2030. With Imipenem Cilastatin Sodium API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Imipenem Cilastatin Sodium API industry.
This Insight Report provides a comprehensive analysis of the global Imipenem Cilastatin Sodium API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Imipenem Cilastatin Sodium API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Imipenem Cilastatin Sodium API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Imipenem Cilastatin Sodium API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Imipenem Cilastatin Sodium API.
United States market for Imipenem Cilastatin Sodium API is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Imipenem Cilastatin Sodium API is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Imipenem Cilastatin Sodium API is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Imipenem Cilastatin Sodium API players cover Shandong New Era Pharmaceutical, Shenzhen Haibin Pharmaceutical, Sinopharm Guorui Pharmaceutical, Taiwan Biotech Co., Ltd. and Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Imipenem Cilastatin Sodium API market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
≥99%
≥98%
Segmentation by application
Pharmaceutical
Research
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Shandong New Era Pharmaceutical
Shenzhen Haibin Pharmaceutical
Sinopharm Guorui Pharmaceutical
Taiwan Biotech Co., Ltd.
Merck
Sun Pharmaceutical Industries Ltd.
JW Pharmaceutical
Zhengde Pharmaceutical
Hospira Inc.
WG Critical Care
Hanhui Pharmaceutical
Zhuhai United Laboratories
ACS Dobfar
Key Questions Addressed in this Report
What is the 10-year outlook for the global Imipenem Cilastatin Sodium API market?
What factors are driving Imipenem Cilastatin Sodium API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Imipenem Cilastatin Sodium API market opportunities vary by end market size?
How does Imipenem Cilastatin Sodium API break out type, application?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Imipenem Cilastatin Sodium API Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Imipenem Cilastatin Sodium API by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Imipenem Cilastatin Sodium API by Country/Region, 2019, 2023 & 2030
2.2 Imipenem Cilastatin Sodium API Segment by Type
2.2.1 ≥99%
2.2.2 ≥98%
2.3 Imipenem Cilastatin Sodium API Sales by Type
2.3.1 Global Imipenem Cilastatin Sodium API Sales Market Share by Type (2019-2024)
2.3.2 Global Imipenem Cilastatin Sodium API Revenue and Market Share by Type (2019-2024)
2.3.3 Global Imipenem Cilastatin Sodium API Sale Price by Type (2019-2024)
2.4 Imipenem Cilastatin Sodium API Segment by Application
2.4.1 Pharmaceutical
2.4.2 Research
2.5 Imipenem Cilastatin Sodium API Sales by Application
2.5.1 Global Imipenem Cilastatin Sodium API Sale Market Share by Application (2019-2024)
2.5.2 Global Imipenem Cilastatin Sodium API Revenue and Market Share by Application (2019-2024)
2.5.3 Global Imipenem Cilastatin Sodium API Sale Price by Application (2019-2024)
3 Global Imipenem Cilastatin Sodium API by Company
3.1 Global Imipenem Cilastatin Sodium API Breakdown Data by Company
3.1.1 Global Imipenem Cilastatin Sodium API Annual Sales by Company (2019-2024)
3.1.2 Global Imipenem Cilastatin Sodium API Sales Market Share by Company (2019-2024)
3.2 Global Imipenem Cilastatin Sodium API Annual Revenue by Company (2019-2024)
3.2.1 Global Imipenem Cilastatin Sodium API Revenue by Company (2019-2024)
3.2.2 Global Imipenem Cilastatin Sodium API Revenue Market Share by Company (2019-2024)
3.3 Global Imipenem Cilastatin Sodium API Sale Price by Company
3.4 Key Manufacturers Imipenem Cilastatin Sodium API Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Imipenem Cilastatin Sodium API Product Location Distribution
3.4.2 Players Imipenem Cilastatin Sodium API Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Imipenem Cilastatin Sodium API by Geographic Region
4.1 World Historic Imipenem Cilastatin Sodium API Market Size by Geographic Region (2019-2024)
4.1.1 Global Imipenem Cilastatin Sodium API Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Imipenem Cilastatin Sodium API Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Imipenem Cilastatin Sodium API Market Size by Country/Region (2019-2024)
4.2.1 Global Imipenem Cilastatin Sodium API Annual Sales by Country/Region (2019-2024)
4.2.2 Global Imipenem Cilastatin Sodium API Annual Revenue by Country/Region (2019-2024)
4.3 Americas Imipenem Cilastatin Sodium API Sales Growth
4.4 APAC Imipenem Cilastatin Sodium API Sales Growth
4.5 Europe Imipenem Cilastatin Sodium API Sales Growth
4.6 Middle East & Africa Imipenem Cilastatin Sodium API Sales Growth
5 Americas
5.1 Americas Imipenem Cilastatin Sodium API Sales by Country
5.1.1 Americas Imipenem Cilastatin Sodium API Sales by Country (2019-2024)
5.1.2 Americas Imipenem Cilastatin Sodium API Revenue by Country (2019-2024)
5.2 Americas Imipenem Cilastatin Sodium API Sales by Type
5.3 Americas Imipenem Cilastatin Sodium API Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Imipenem Cilastatin Sodium API Sales by Region
6.1.1 APAC Imipenem Cilastatin Sodium API Sales by Region (2019-2024)
6.1.2 APAC Imipenem Cilastatin Sodium API Revenue by Region (2019-2024)
6.2 APAC Imipenem Cilastatin Sodium API Sales by Type
6.3 APAC Imipenem Cilastatin Sodium API Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Imipenem Cilastatin Sodium API by Country
7.1.1 Europe Imipenem Cilastatin Sodium API Sales by Country (2019-2024)
7.1.2 Europe Imipenem Cilastatin Sodium API Revenue by Country (2019-2024)
7.2 Europe Imipenem Cilastatin Sodium API Sales by Type
7.3 Europe Imipenem Cilastatin Sodium API Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Imipenem Cilastatin Sodium API by Country
8.1.1 Middle East & Africa Imipenem Cilastatin Sodium API Sales by Country (2019-2024)
8.1.2 Middle East & Africa Imipenem Cilastatin Sodium API Revenue by Country (2019-2024)
8.2 Middle East & Africa Imipenem Cilastatin Sodium API Sales by Type
8.3 Middle East & Africa Imipenem Cilastatin Sodium API Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Imipenem Cilastatin Sodium API
10.3 Manufacturing Process Analysis of Imipenem Cilastatin Sodium API
10.4 Industry Chain Structure of Imipenem Cilastatin Sodium API
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Imipenem Cilastatin Sodium API Distributors
11.3 Imipenem Cilastatin Sodium API Customer
12 World Forecast Review for Imipenem Cilastatin Sodium API by Geographic Region
12.1 Global Imipenem Cilastatin Sodium API Market Size Forecast by Region
12.1.1 Global Imipenem Cilastatin Sodium API Forecast by Region (2025-2030)
12.1.2 Global Imipenem Cilastatin Sodium API Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Imipenem Cilastatin Sodium API Forecast by Type
12.7 Global Imipenem Cilastatin Sodium API Forecast by Application
13 Key Players Analysis
13.1 Shandong New Era Pharmaceutical
13.1.1 Shandong New Era Pharmaceutical Company Information
13.1.2 Shandong New Era Pharmaceutical Imipenem Cilastatin Sodium API Product Portfolios and Specifications
13.1.3 Shandong New Era Pharmaceutical Imipenem Cilastatin Sodium API Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Shandong New Era Pharmaceutical Main Business Overview
13.1.5 Shandong New Era Pharmaceutical Latest Developments
13.2 Shenzhen Haibin Pharmaceutical
13.2.1 Shenzhen Haibin Pharmaceutical Company Information
13.2.2 Shenzhen Haibin Pharmaceutical Imipenem Cilastatin Sodium API Product Portfolios and Specifications
13.2.3 Shenzhen Haibin Pharmaceutical Imipenem Cilastatin Sodium API Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Shenzhen Haibin Pharmaceutical Main Business Overview
13.2.5 Shenzhen Haibin Pharmaceutical Latest Developments
13.3 Sinopharm Guorui Pharmaceutical
13.3.1 Sinopharm Guorui Pharmaceutical Company Information
13.3.2 Sinopharm Guorui Pharmaceutical Imipenem Cilastatin Sodium API Product Portfolios and Specifications
13.3.3 Sinopharm Guorui Pharmaceutical Imipenem Cilastatin Sodium API Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Sinopharm Guorui Pharmaceutical Main Business Overview
13.3.5 Sinopharm Guorui Pharmaceutical Latest Developments
13.4 Taiwan Biotech Co., Ltd.
13.4.1 Taiwan Biotech Co., Ltd. Company Information
13.4.2 Taiwan Biotech Co., Ltd. Imipenem Cilastatin Sodium API Product Portfolios and Specifications
13.4.3 Taiwan Biotech Co., Ltd. Imipenem Cilastatin Sodium API Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Taiwan Biotech Co., Ltd. Main Business Overview
13.4.5 Taiwan Biotech Co., Ltd. Latest Developments
13.5 Merck
13.5.1 Merck Company Information
13.5.2 Merck Imipenem Cilastatin Sodium API Product Portfolios and Specifications
13.5.3 Merck Imipenem Cilastatin Sodium API Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Merck Main Business Overview
13.5.5 Merck Latest Developments
13.6 Sun Pharmaceutical Industries Ltd.
13.6.1 Sun Pharmaceutical Industries Ltd. Company Information
13.6.2 Sun Pharmaceutical Industries Ltd. Imipenem Cilastatin Sodium API Product Portfolios and Specifications
13.6.3 Sun Pharmaceutical Industries Ltd. Imipenem Cilastatin Sodium API Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Sun Pharmaceutical Industries Ltd. Main Business Overview
13.6.5 Sun Pharmaceutical Industries Ltd. Latest Developments
13.7 JW Pharmaceutical
13.7.1 JW Pharmaceutical Company Information
13.7.2 JW Pharmaceutical Imipenem Cilastatin Sodium API Product Portfolios and Specifications
13.7.3 JW Pharmaceutical Imipenem Cilastatin Sodium API Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 JW Pharmaceutical Main Business Overview
13.7.5 JW Pharmaceutical Latest Developments
13.8 Zhengde Pharmaceutical
13.8.1 Zhengde Pharmaceutical Company Information
13.8.2 Zhengde Pharmaceutical Imipenem Cilastatin Sodium API Product Portfolios and Specifications
13.8.3 Zhengde Pharmaceutical Imipenem Cilastatin Sodium API Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Zhengde Pharmaceutical Main Business Overview
13.8.5 Zhengde Pharmaceutical Latest Developments
13.9 Hospira Inc.
13.9.1 Hospira Inc. Company Information
13.9.2 Hospira Inc. Imipenem Cilastatin Sodium API Product Portfolios and Specifications
13.9.3 Hospira Inc. Imipenem Cilastatin Sodium API Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Hospira Inc. Main Business Overview
13.9.5 Hospira Inc. Latest Developments
13.10 WG Critical Care
13.10.1 WG Critical Care Company Information
13.10.2 WG Critical Care Imipenem Cilastatin Sodium API Product Portfolios and Specifications
13.10.3 WG Critical Care Imipenem Cilastatin Sodium API Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 WG Critical Care Main Business Overview
13.10.5 WG Critical Care Latest Developments
13.11 Hanhui Pharmaceutical
13.11.1 Hanhui Pharmaceutical Company Information
13.11.2 Hanhui Pharmaceutical Imipenem Cilastatin Sodium API Product Portfolios and Specifications
13.11.3 Hanhui Pharmaceutical Imipenem Cilastatin Sodium API Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Hanhui Pharmaceutical Main Business Overview
13.11.5 Hanhui Pharmaceutical Latest Developments
13.12 Zhuhai United Laboratories
13.12.1 Zhuhai United Laboratories Company Information
13.12.2 Zhuhai United Laboratories Imipenem Cilastatin Sodium API Product Portfolios and Specifications
13.12.3 Zhuhai United Laboratories Imipenem Cilastatin Sodium API Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Zhuhai United Laboratories Main Business Overview
13.12.5 Zhuhai United Laboratories Latest Developments
13.13 ACS Dobfar
13.13.1 ACS Dobfar Company Information
13.13.2 ACS Dobfar Imipenem Cilastatin Sodium API Product Portfolios and Specifications
13.13.3 ACS Dobfar Imipenem Cilastatin Sodium API Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 ACS Dobfar Main Business Overview
13.13.5 ACS Dobfar Latest Developments
14 Research Findings and Conclusion